The Motley Fool

Three big-yielding dividend stocks I’d happily buy and hold for 5, 10 and 25 years

Image source: Getty Images.

Unite Group (LSE: UTG) is a share that I’d be content to hold for the next five years as the stream of students to British universities flows on and on.

The student accommodation provider continues to thrive because of solid ‘digs’ demand from both domestic and foreign students. This was shown in trading commentary last month in which chief financial officer Joe Lister declared that “bookings for the 2019/20 academic year have started strongly with 67% of rooms already sold, with 57% guaranteed by nominations agreements at rental levels that are supportive of delivering rental growth in line with our target of 3.0-3.5%.”

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

The implications of Brexit on broader immigration is uncertain. But I’m not expecting it to have a devastating effect on student numbers from abroad, at least not in the short- to-medium-term. I think the FTSE 250 firm should still deliver strong shareholder returns for a little while longer at least. And a 3.7% forward dividend yield makes it look mighty attractive, too.

I own this!

So great is Britain’s need to build houses that I’d be happy to cling onto Ibstock (LSE: IBST) — a stock that I grabbed a slice of in the spring of 2017 — for at least another 10 years. I was tempted in by its big dividends and, as I type, the prospective yield stands at a titanic 6.1%.

Just how ineffective government housing policy has been to meet the accommodation of a growing population is no secret. Report after report reveals the scale of the problem and has led to the current Tory administration to pledge 300,000 new homes to be built per year by the middle of the next decade.

Ibstock’s bricks, then, look set to remain in strong demand. A mix of price improvements and rising volumes helped revenues rise 8% in 2018. And the opening of its Leicestershire mega-factory last July, a move that doubled production capacity, will put it in great shape to keep growing sales in the years ahead.

A Footsie favourite

GlaxoSmithKline (LSE: GSK) is another share I’d be happy to hold tightly onto for many years in the future. Indeed, given its position at the coalface of pharmaceutical innovation, it’s a share I can see delivering exceptional shareholder returns over the next 25 years, at least.

Medical care is one of things that we can simply not do without, obviously. Good health for us and our loved ones is the number-one priority, meaning that GlaxoSmithKline’s products keep flying off chemists’ shelves, irrespective of broader economic turmoil in certain regions. In fact, the FTSE 100 company’s global sales outlook is getting better and better as wealth levels in emerging markets rise.

The drugs giant saw constant-currency sales to developing regions rise 4% in 2018, it announced this week. I’m expecting its sales performance to pick up, too, following new chief executive Emma Walmsley’s vow to shake up GlaxoSmithKline’s strategy in exciting growth regions, such as Africa. I feel it’s a great blue-chip to pick up today, its appeal boosted by a giant forward dividend yield of 5.1%.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Royston Wild owns shares of Ibstock. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.